XML 25 R16.htm IDEA: XBRL DOCUMENT v3.22.1

Stockholders Equity (Tables)

3 Months Ended

Mar. 31, 2022

Stockholders Equity (Tables) [Line Items]

Schedule of outstanding warrants

Warrant

Issuance Date

Expiration Date

Exercise Price Per Share

Number of Shares of Common Stock Underlying Warrants

Private Placement Warrants

IPO (December 13, 2018)

December 13, 2023

11.50

2,900,000

Public Warrants

IPO (December 13, 2018)

October 28, 2024

11.50

3,500,000

2021 Registered Direct Offering Warrants

SPA (July 28, 2021)

January 28, 2027

5.00

2,812,501

9,212,501

Schedule of black-scholes option-pricing model

		Three Months Ended March 31,
		2022				2021
Underlying value of Common Stock ($)			1.41				7.02
Exercise price ($)			1.41				7.02
Expected volatility (%)			85.3				85.0
Expected terms of the option (years)			6.11				6.11
Risk-free interest rate (%)			2.50				1.17

Schedule of options granted to purchase common stock

		For the Three Months Ended March 31, 2022
		Number of Options				Weighted Average Exercise Price				Aggregate Intrinsic Value
Outstanding at the beginning of period			4,084,549			$	3.95			$	671
Granted			1,153,500			$	1.41
Forfeited			(88,399	)		$	6.38
Exercised			-			$	-
Outstanding at the end of period			5,149,650			$	3.34			$	888
Exercisable at the end of period			2,801,390
Weighted average remaining contractual life of outstanding options – years as of March 31, 2022			7.25

Schedule of share-based payment expenses

		Three Months Ended March 31,
		2022				2021
Research and development expenses, net			258				331
General and administrative			357				199
			615				530

Warrant [Member]

Stockholders Equity (Tables) [Line Items]

Schedule of outstanding warrants

Warrant

Issuance Date

Expiration Date

Exercise Price Per Share

Number of Shares of Common Stock Underlying Warrants

Private Warrants issued to scientific founders (see below)

November 27, 2017

-

2,974

X

- References

No definition available.

+ Details

Name:	phge_StockholdersEquityTablesLineItems
Namespace Prefix:	phge_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

+ Details

Name:	us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

+ Details

Name:	us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the change in stock options.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section S99
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775

+ Details

Name:	us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: